Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Revenue of Acumen Pharmaceuticals, Inc. (ABOS)
Revenue in 2023 (TTM): $
According to Acumen Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Acumen Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-42,318,000 | $-61,077,000 | $-52,371,000 | $-52,371,000 |
| 2022 | $ | $-169,000 | $-45,068,000 | $-42,856,000 | $-40,475,000 |
| 2021 | $ | $-4,000 | $61.58 M | $-100,606,000 | $-181,679,000 |
| 2020 | $1.44 M | $1.43 M | $-8,498,000 | $-7,325,000 | $-7,324,000 |
| 2019 | $1.7 M | $1.69 M | $-7,658,000 | $-7,907,000 | $-7,862,000 |